Argenta Announces Drug Discovery Agreement with Cellzome
News Sep 05, 2005
Argenta Discovery has announced that it has entered into drug discovery collaboration with Cellzome, Inc.
Under the terms of the agreement Argenta will apply its integrated medicinal chemistry, assay development and screening capabilities and collaborate with Cellzome’s scientists in the search for disease therapies.
The deal also provides Cellzome with access to Argenta's other integrated scientific disciplines including ADME/PK.
Dr Chris Ashton, Argenta's CEO, said, “We are delighted that one of Europe's leading biotechnology companies has chosen to work with Argenta.”
He adds, “This new agreement illustrates Argenta’s excellence in providing fully integrated collaborative drug discovery solutions.”
Further he said, “Last year our contract research business revenue grew by over 25% and we have had an excellent start to the new financial year: this being the third collaborative agreement we have signed in the last five months.”
Tim Edwards, CEO of Cellzome, added, “We chose to work with Argenta because of the experience of the Argenta team; they can provide us with high quality, reproducible results.”
He adds, "This collaboration will further extend and compliment our own drug discovery unit and will help us move our projects forwards into the clinic."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019